The level of TNF soluble receptor type 1 in patients with systemic sclerosis

Abstract


Aim. To study content and clinical correlations ofsTNF-RI in patients with systemic sclerosis (SS). Material and methods. Thirty nine SS patients were examined with enzyme immunoassay for serum levels of sTNF-RIand soluble adhesion molecules (sSAM) sVSAM-1, sISAM-1 and sR-selectine using R&D System kits (USA). The control group consisted of 14 healthy subjects (donors). Content of sTNF-RI and sSAM was considered as elevated if it exceeded relevant mean values by 1SD. Results. sTNF-RI content was significantly higher in the patients than in the controls (p = 0.0001) and was similar inpatients with diffuse and limited forms of the disease. A rise in sTNF-RI correlated with a rise in pulmonary artery pressure. In patients with pulmonary hypertension or restrictive pulmonary affection sTNF-RIwas higher than in patients free of pulmonary hypertension or impaired external respiration function. A marked correlation was found between sTNF-RI and sVSAM-1. Patients with high CRP had significantly higher sTNF-RI level than patients with normal CRP. Conclusion. SS is characterized by elevated content ofsTNF-RI. This content may serve a diagnostic marker of the disease progression.

References

  1. LeRoy E. С., Smith E. A., Kahaleh М. В. et al. A strategy for determining the pathogenesis of systemic sclerosis. Arthr. and Rheum. 1989; 32: 817-825.
  2. Black С. М. The aetiopathogenesis of systemic sclerosis. J. Roy. Coll. Physic. Lond. 1995; 29: 119-130.
  3. Pober J. S. Endothelial activation: intracellular signalling pathways. Arthr. Res. 2002; 4 (suppl. 3): S109-S116.
  4. Cope A. P. Studies of T-cell activation in chronic inflammation. Arthr. Res. 2002; 4 (suppl. 3): S197-S211.
  5. Zhang M., Tracey K. J. Tumor necrosis factor. In: Thopson A., ed. The cytokine handbook. 3-rd ed. San Diego, Calif.: Academic Press; 1998. 517-548.
  6. Umehara H., Kumagai S., Murakami M. et al. Enhanced production of interleukin-l and tumor necrosis factor alpha by cultured peripheral blood monocytes from patients with scleroderma. Arthr. and Rheum. 1990; 33 (6): 893-897.
  7. Kantor Т. V., Friberg D., Medsger Т. A. Jr. et al. Cytokine production and serum levels in systemic sclerosis. Clin. Immunol. Immunopathol. 1992; 65 (3): 278-285.
  8. Kadono Т., Kikuchi K., Ihn H. et al. Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J. Rheumatol. 1998; 25 (2): 296-301.
  9. Gruschwitz M. S., Vieth G. Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interferon-gamma and tumor necrosis factor alpha in the early disease stage. Arthr. and Rheum. 1997; 40 (3): 540-550.
  10. Cho M. M., Jimenez S. A., Johnson B. A. et al. In vitro cytokine modulation of intercellular adhesion molecule-1 expression on systemic sclerosis dermal fibroblasts. Pathobiology 1994; 62 (2): 73-81.
  11. Hasegawa M., Fujimoto M., Kikuchi K., Takehara K. Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis. J. Rheumatol. 1997; 24 (4): 663-665.
  12. Van Zee K. J., Kohno Т., Fisher E. et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc. Natl. Acad. Sci. USA 1992; 89: 4845-4849.
  13. Van Zee K. J., Stackpole S. A., Montegur W. J. et al. A human tumor necrosis factor (TNF) mutant that binds exclusively to the p55 TNF receptor produces toxicity in the baboon. J. Exp. Med. 1994; 179: 1185-1191.
  14. Sheehan K. C., Pinckard J. K., Arthur С. D. et al. Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75. J. Exp. Med. 1995; 181:607-617.
  15. Heilig В., Fiehn C., Brockhaus M. et al. Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematodes, progressive systemic sclerosis, and mixed connective tissue disease. J. Clin. Immunol. 1993; 13 (5): 321-328.
  16. Majewski S., Wojas-Pelc A., Malejczyk M. et al. Serum levels of soluble TNF alpha receptor type I and the severity of systemic sclerosis. Acta Dermato-Venereol. 1999; 79 (3): 207-210.
  17. D'Elios M. M., Romagnani P., Scaletti С. et al. In vivo CD30 expression in human diseases with predominant activation of Th2-like T cells. J. Leukoc. Biol. 1997; 61 (5): 539-544.
  18. Gruschwitz M. S., Albrecht M., Vieth G., Haustein U. F. In situ expression and serum levels of tumor necrosis factor-alpha receptors in patients with early stages of systemic sclerosis. J. Rheumatol. 1997; 24 (10): 1936-1943.
  19. MasiA. Т., Rodnan G. P., Medsger T. A. et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthr. and Rheum. 1980; 23: 581-590.
  20. LeRoy E. C., Black С. М., Fleischmajer R. et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 1988; 15: 202-205.
  21. Valentini G., Delia Rossa A., Bombardieri S. et al. European multicenter study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann. Rheum. Dis. 2001; 60: 592-598.
  22. Kahaleh M. В., Sultany G. L., Smith E. A. et al. A modified scledroderma skin scoring method. Clin. Exp. Rheumatol. 1986; 4: 367-369.
  23. Bevilacqua M. P., Pober J. S., Wheeler M. E. et al. Interleukin1 acts on cultured human vascular endothelial cells to increase the adhesion of polymorphonuclear leukocytes, monocytes and related leukocyte cell lines. J. Clin. Invest. 1985; 76: 2003- 2011.
  24. Pober J. S., Cotran R. S. Cytokines and endothelial cell biology. Physiol. Rev. 1990; 70: 427-451.
  25. Denton С. P., Bickerstaff M. С. М., Shiwen X. et al. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br. J. Rheumatol. 1995; 34 (11): 1048-1054.
  26. Bolster M. В., Ludwicka A., Sutherland S. E. et al. Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthr. and Rheum. 1997; 40 (4): 743-751.
  27. Pantelidis P., McGrath D. S., Southcott A. M. et al. Tumour necrosis factor-alpha production in fibrosing alveolitis is macrophage subset specific. Respir. Res. 2001; 2 (6): 365-372.

Statistics

Views

Abstract - 92

Cited-By


Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2020 Alekperov R.Т., Timchenko A.V., Samsonov M.Y., Guseva N.G., Nasonov E.L.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies